Marco Meglio

Over a 24-month treatment period, apitegromab-treated patients showed improvements on PEDI-CAT and PROMIS, measures of activities of daily living, and ESBBT, a muscle endurance measurement tool.

Foralumab, an anti-CD3 monoclonal antibody, has been previously assessed in diseases such as progressive multiple sclerosis and Crohn disease, as well as in patients with mild to moderate COVID-19.

Within 5 years after the index date, the lowest proportion of epilepsy diagnoses were among those treated with angiotensin receptor blockers and highest in those on ß-blockers and calcium channel blockers.

Changes in plasma pTau217 and GFAP levels from donanemab significantly correlated with percent change in amyloid plaque level as measured by amyloid PET imaging.

The composite score, which consisted of 6 linguistic features and 3 acoustic features, was shown to be sensitive to measures of disease progression, with a potential to help understand treatment response.

In a traditional placebo-controlled trial, Nerivio outperformed placebo in the reduction monthly migraine days and monthly headache days, regardless of chronic or episodic migraine status.

For patients who rolled over to the ARC-HD extension study from the previous First-HD trial, there was a 4.5-point reduction in mean chorea scores at week 8 that were maintained through week 145.

When asked which efficacious diagnostic or treatment options they hope to see in the future, a majority of physicians, especially specialists, expressed a desire to see more useful biomarkers, followed by more effective diagnostic tests overall.

Although neurodevelopmental disorders were common in those on antidepressants, the crude hazard ratios were substantially attenuated after adjustment for measured covariates and proxies for unmeasured covariates.

After a successful phase 1 study in which PTC518 reduced huntingtin protein by 30% to 50%, the company is pausing the US enrollment of its phase 2 study until additional data is provided to the FDA.

More than 40% of patients with ASPECTS scores between 4 and 5 treated with EVT showed functional outcome improvements, whereas slightly over 20% of those with scores between 0 to 3 demonstrated the same.

The adult neurologist at Allegheny Health Network discussed the ever-changing landscape of therapies for myasthenia gravis and shift toward more holistic disease management.

In a phase 2 study, fosgonimeton showed positive effects on measures of cognition, function, and neurodegeneration when taken as a monotherapy, prompting an unblinded interim analysis.

EDG-5506, an orally administered small molecule agent, showed nearly a 40% decrease in levels of serum creatine kinase in a phase 1b trial of adults with Becker muscular dystrophy.

In an open-label extension trial, tofersen showed significant reductions in SOD1 protein and neurofilament light over a 12-month period. It is now expected to be reviewed by the FDA by early Q2 2023.

The launch of the medication was done in phases, as wholesalers received first-line formulary coverage in September 2022, while a nationwide launch is expected in 2023.

P100 amplitude of 15 minute checks in the NMOSD-ON group had a significant reduction at 6 months relative to the IDON group, suggesting more several axonal damage.

Over a 2-year treatment period, discontinuation rates with risdiplam were low, and observed adverse events and serious AEs resembled previously conducted studies.

Annualized relapse rates were elevated compared with the prepregnancy period, especially during the initial 3 months after delivery, whereas EDSS scores worsened during pregnancy and the postpartum period.

The odds of having memory worsening at follow-up after 3 years were almost 30% greater for those who exhibited deteriorating insomnia status than those who showed signs of improvement.

Similar to the recently commenced phase 2b LUMA study, BIIB122, an investigational small molecule inhibitor of LRRK2, will be evaluated in a cohort of 400 individuals with genetically mutated Parkinson disease.

The division chief of stroke and vascular neurology at Duke Health discussed how clinicians have typically treated poststroke motor symptoms and how technology is expanding these capabilities.

Valproic acid, which had been associated with a variety of major and minor malformations in pregnancy, remained barely unchanged in terms of use, dropping slightly from 12.4% to 10.1% over the 5-year period.

Joe Kardine, MS, OTR, CBIS, the clinical program manager at the Jefferson Center for Neurorestoration, discussed the influx of new neurorestorative technology and the future of treating patients with functional loss.

In a cohort of nearly 600,000 individuals, the combination of dementia diagnosis and presence of psychiatric comorbidity significantly increased the risk of suicide.

Enrollment for the phase 1/2 study will be partially stopped; however, all participants included in the trial, whether on AOC 1001 or placebo, are eligible to continue their current dosing regimen.

Using magnetic resonance spectroscopy, investigators observed significantly different levels of total NAA across MS and NMOSD subtypes, and a negative correlation between total NAA and disability score.

When hydromethylthionine mesylate was compared with publicly available placebo decline data, the treatment effects of cognitive and functional decline are about 3-fold larger over 18 months.

Nicholas Silvestri, MD, clinical professor at the University at Buffalo discussed topics related to the expansion of treatments for myasthenia gravis and the positive outlook of managing the disease.

The clinical program manager at the Jefferson Center for Neurorestoration discussed a new approach to restoring arm function using a powered arm brace and muscle stimulation system.